Pharmacokinetics of orally administered pirfenidone in male and female beagles

Journal of Veterinary Pharmacology and Therapeutics

Volumn 27, Issue 5, 2004, Pages 361-367

  Bruss, M L ^a   Margolin, S B ^b   Giri, S N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Marnac Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; PIRFENIDONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENDER; MALE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; MALE; PYRIDONES; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; CANIS FAMILIARIS;

EID: 8344247705     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2004.00612.x     Document Type: Article

References (18)

1. Boxenbaum, H. (1984) Interspecies pharmacokinetic scaling and the evolutionary comparative paradigm. Drug Metabolism Review, 15, 1071-1121.
2. Duffull, S.B., Begg, E.J. & Deely, J.J. (1999) Development of a general method of limited sampling for the determination of AUC for a drug that displays two-compartment pharmacokinetics. European Journal of Clinical Pharmacology, 55, 213-219.
3. Giri, S.N., Wang, Q., Xie, Y., Lango, J., Morin, D., Margolin, S.B. & Buckpitt, A.R. (2002) Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharmaceutics and Drug Disposition, 23, 203-211.
4. Iyer, S.N., Wild, J.S., Schiedt, M.J., Hyde, D.M., Margolin, S.B. & Giri, S.N. (1995) Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. Journal of Laboratory and Clinical Medicine, 125, 779-785.
5. Iyer, S.N., Margolin, S.B., Hyde, D.M. & Giri, S.N. (1998) Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin hamster model. Experimental Lung Research, 24, 119-132.
6. Kedderis, G. L. & Held, S. D. (1996) Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicology and Applied Pharmacology, 140, 124-130.
7. Kehrer, J.P. & Margolin, S.B. (1997) Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicology Letters, 90, 125-132.
8. Kleinbaum, D.G., Kupper, L.L., Muller, K.E. & Nizam, A. (1998) Applied Regression Analysis and Multivariable Methods. 3rd edn. pp. 322-327. Duxbury Press, Pacific Grove, CA.
9. Levi, M., Knol, J. A., Ensminger, W. D., Deremer, S. J., Dou, C., Lunte, S. M., Bonner, H. S., Shaw, L. M. & Smith D. E. (2002) Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys. Drug Metabolism and Disposition, 30, 1425-1430.
10. max) in toxicokinetics. Journal of Pharmaceutical Sciences, 86, 579-583.
11. Margolin, S.B. (2002) Pirfenidone Investigational New Drug Brochure, pp. 113, 114, 385. Marnac, Inc., Dallas, CA.
12. Miric, G., Dallemagne, C., Endre, Z., Margolin, S., Taylor, S.M. & Brown. L. (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. British Journal of Pharmacology, 133, 687-694.
13. Raghu, G., Johnson, W.C., Lockhart, D. & Mageto, Y. (1999) Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. American Journal of Respiratory and Critical Care Medicine, 159, 1061-1069.
14. Rowland, M. & Tozer, T.N. (1995) Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. pp. 424-442, 469-470. Williams and Wilkins, Baltimore, MD.
15. Tada, S., Nakamuta, M., Enjoji, M., Sugimoto, R., Iwamoto, H., Kato, M., Nakashima, Y. & Nawata, H. (2001) Pirfenidone inhibits dimethylnitrosamine- induced hepatic fibrosis in rats. Clinical Experimental Pharmacology and Physiology, 28, 522-527.
16. Taniyama, M., Ohbayashi, S., Narita, M., Nakazawa, R., Hasegawa, S., Azuma, N., Teraoka, S., Ota, K., Yamauchi, S. & Margolin, S.B. (1997) Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. European Journal of Clinical Pharmacology, 52, 77-78.
17. Walker, J.E. and Margolin, S.B. (2001) Pirfenidone for chronic progressive multiple sclerosis. Multiple Sclerosis, 7, 305-312.
18. Wilkinson, G.R. and Shand, D.G. (1975) A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics, 18, 377-390.